Molbio Diagnostics Eyes ₹940 Crore Through IPO for Growth and Stake Reduction
Molbio Diagnostics plans a ₹940 crore IPO to fund expansion and reduce promoter stake, targeting high-risk investors.
Molbio Diagnostics, a leading player in molecular diagnostics, is set to raise ₹940 crore through an initial public offering (IPO) aimed at enhancing its capital expenditures and reducing promoter stakes. The company, which has established a significant presence in over 90 countries, plans to secure ₹200 crore via fresh issuance of shares and an additional ₹740 crore through an offer for sale.
Expanding Global Footprint
Founded in 2000, Molbio has carved a niche in the diagnostics market with its innovative solutions for infectious and non-communicable diseases. The company operates six manufacturing sites globally, supplying to government health programs, diagnostic labs, hospitals, and international healthcare organizations. Its flagship product, the 'Truenat' platform, provides rapid and accurate diagnostics, especially in resource-limited settings.
Molbio's revenue has witnessed significant growth, largely driven by its tuberculosis diagnostic test kits. In the fiscal years 2024 to 2026, the company's revenue surged by 31.5% annually, reaching ₹1,445.7 crore, while net profits climbed 40.2% to ₹164.1 crore. The EBITDA margin also saw an increase, rising to 22.6% in FY26 from 22% in FY24.
Investor Considerations
Post-IPO, the promoter group's stake in Molbio will decrease from 46.6% to 43%. This move is part of a broader strategy to diversify the company's shareholder base and attract high-risk investors looking for long-term growth opportunities. The company's reliance on major clients, which contribute over half of its revenue, highlights the potential risks and rewards for investors.
Molbio's valuation demands a price-earnings (P/E) multiple of up to 57, a figure comparable to other key players in the healthcare diagnostics sector such as Poly Medicure and Dr. Lal PathLabs, which trade at P/E multiples ranging from 54 to 81.
Market Position and Future Prospects
The company derives nearly 74% of its revenue from the sale of test kits, with a substantial portion coming from tuberculosis diagnostics. Molbio's strategic collaborations and subsidiaries further enhance its offerings, which include radiology, digital pathology, and breast health screening solutions.
With its robust financial performance and strategic market positioning, Molbio Diagnostics presents a compelling case for investors willing to navigate the risks associated with high-growth sectors. As the global demand for advanced diagnostic solutions continues to rise, Molbio's innovative technologies and expanding global footprint could drive significant growth in the coming years.